查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471211

原电池市场：按原产地、电池类型和最终用户划分 - 2024-2030 年全球预测

Primary Cells Market by Origin (Animal Primary Cells, Human Primary Cells), Cell Type (Dermatocytes, Gastrointestinal Cells, Heart Cells), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年原电池市场规模为14.3亿美元，预计2024年将达16亿美元，2030年将达31.8亿美元，复合年增长率为12.10%。

原代细胞是组织和器官的基本组成部分，表现出与其起源相似的自然生物学行为，使其成为各种科学应用中的重要工具。对再生医学和细胞研究的投资不断增加，推动了开发原代细胞创新治疗解决方案的需求。 CRISPR基因编辑技术等技术进步为标靶治疗提供了更精确的操作工具，从而扩大了原代细胞的用途。然而，由于影响其生物学的遗传和环境因素，原代细胞可能表现出供体之间的变异性，这可能会限制研究环境中的重现性。然而，学术机构、实验室和生物製药製造商之间日益加强的生命科学合作预计将有助于寻找主要的细胞治疗方法。

主要市场统计
基准年[2023] 14.3亿美元
预测年份 [2024] 16亿美元
预测年份 [2030] 31.8亿美元
复合年增长率（%） 12.10%

起源：越来越偏好原代人类细胞以准确地代表人类细胞反应

原代动物细胞直接从动物组织中分离出来，保留了许多原始的生理特性，使其成为体外和临床前研究的宝贵工具。研究人员通常使用原代动物细胞来研究生物过程、筛检药物和开发新的疾病治疗方法。使用动物原代细胞的优点包括易于取得、与人类原代细胞相比成本低廉以及能够模拟物种特异性的治疗反应。人类原代细胞直接源自人体组织，并保留了许多与其来源组织相似的特征。对于理解人类生物学、药物发现、病理学、毒性测试和再生医学应用至关重要。与永生化细胞株或动物模型相比，原代人类细胞培养物可以更准确地代表人类细胞反应。对于需要更高生物学相关性的应用，尤其是研究人类特异性疾病和开发患者治疗方法，原代人类细胞通常是首选。

细胞类型：在药物开发和毒性测试中增加皮肤细胞的使用

皮肤细胞对于皮肤生物学、创伤治疗和皮肤疾病的研究人员至关重要。它也广泛应用于药物开发和毒性测试。胃肠细胞包括胃肠道中存在的各种类型的细胞，对于肠道健康、营养吸收和胃肠道疾病的研究至关重要。心肌细胞或心肌细胞是涉及心臟发育、功能和疾病建模的心血管研究的核心。造血干细胞（造血干细胞）可产生所有类型的血细胞，在再生医学以及白血病和淋巴瘤等血液疾病的移植治疗中具有多种应用。原代肝细胞对于涉及肝功能、代谢和药物毒性测试的研究至关重要。肺部研究在很大程度上依赖原代肺细胞来研究气喘、慢性阻塞性肺病和肺癌等呼吸道疾病。肌肉骨骼细胞由形成骨骼、软骨和肌肉的细胞组成，对于肌肉骨骼疾病、再生医学应用和组织工程解决方案的研究至关重要。我们描述了一个富有洞察力的肾病学研究模型，包括肾臟或肾原代细胞肾病变进展和肾功能药物毒性评估。

最终用户：扩大原代细胞在生命科学公司中的使用可确保实验过程中获得准确的结果。

生技、製药和医疗设备等生命科学公司在研发活动上投入大量资金。这些公司需要原代细胞来进行药物发现、毒性测试、细胞疗法开发、再生医学应用和生物产品製造。这些公司需要具有良好表型的高品质原代细胞，以便在实验过程中获得准确的结果。研究机构包括专注于阐明基本生物过程和疾病机制的学术机构和政府资助的实验室。原代细胞对于研究工作至关重要，因为它们作为模型系统来研究各种实验条件下的细胞过程和反应。研究机构喜欢符合伦理且有适当文件记录的多样化原代细胞，以确保不同实验室之间的可重复性。

区域洞察

美洲地区显示出显着的成长，主要是由于美国和加拿大等国家成熟的生物技术和製药行业的存在。细胞培养方法中先进技术的快速采用以及研发活动投资的增加对该地区的强劲表现做出了贡献。此外，旨在推广使用原代细胞的新型治疗方法的政府倡议正在推动这一领域的成长。在亚太地区，中国和印度等国家的生物製药领域正在经历显着扩张。这是由于老年人口不断增加，慢性病盛行率很高，需要创新的治疗方法、医疗成本不断上升以及对研发活动的关注增加。因此，该地区对原电池的需求正在迅速增加。此外，日本在再生医学研究方面拥有强大的影响力，且原代细胞用于治疗目的的使用正在增加。由于政府和私人组织大量投资支持的强大研发框架，欧洲正在经历显着成长。德国、法国、义大利、英国、西班牙和荷兰等国家透过各自的生物製药产业做出了巨大贡献，塑造了欧洲、中东和非洲地区的整体进步格局。

FPNV定位矩阵

FPNV定位矩阵对于评估原代细胞市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对原电池市场供应商的现状进行富有洞察力和深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动和突破性产品开发的智力见解。

本报告解决了以下关键问题：

1.原电池市场规模及预测是多少？

2.在原电池市场预测期内，我们应该考虑投资哪些产品和应用？

3.原代细胞市场的技术趋势和法规结构是什么？

4.原电池市场主要厂商的市场占有率为何？

5.进入原代细胞市场的合适形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 药物筛检和细胞检测的普及
      • 与现有方法相比，人类原代细胞的优势
      • 单株抗体和个人化医疗日益受到关注
    • 抑制因素
      • 常见的细胞培养问题，例如污染
    • 机会
      • 生物技术和生物製药产业的扩张
      • 使用原代细胞进行生物医学研究的进展
    • 任务
      • 细胞生物学研究领域的伦理问题
  • 市场区隔分析
    • 起源：人们越来越倾向于使用原代人类细胞来准确地代表人类细胞反应
    • 细胞类型：在药物开发和毒性测试中更多地使用皮肤细胞
    • 最终用户：生命科学公司对原代细胞的使用激增，以确保实验过程中获得准确的结果
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章原代细胞市场：依来源分类

  • 介绍
  • 动物
  • 人类

第七章原代电池市场：依电池类型

  • 介绍
  • 皮肤细胞
  • 胃肠细胞
  • 心臟细胞
  • 造血细胞
  • 肝细胞
  • 肺细胞
  • 肌肉骨骼细胞
  • 肾臟细胞

第 8 章 原电池市场：依最终用户分类

  • 介绍
  • 生命科学公司
  • 研究机构

第九章美洲原代细胞市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太原电池市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲原电池市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4F4C36263622

[195 Pages Report] The Primary Cells Market size was estimated at USD 1.43 billion in 2023 and expected to reach USD 1.60 billion in 2024, at a CAGR 12.10% to reach USD 3.18 billion by 2030.

Primary cells are the fundamental building blocks of tissues and organs and exhibit natural biological behavior similar to their origin, making them an essential tool in various scientific applications. Increased investment in regenerative medicine and cell-based research drives primary cells' need to develop innovative therapeutic solutions. Technological advancements such as CRISPR gene-editing techniques have expanded primary cell usage by offering more precise manipulation tools for targeted therapies. However, primary cells may exhibit donor-to-donor variability due to genetic and environmental factors influencing their biology, potentially limiting their reproducibility in research settings. Nevertheless, the increasing number of life sciences collaborations between academic institutions, research laboratories, and biopharmaceutical manufacturers is expected to contribute to exploring primary cell-based therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.60 billion
Forecast Year [2030] USD 3.18 billion
CAGR (%) 12.10%

Origin: Increasing preference for human primary cells for accurate representations of human cellular responses

Animal primary cells are isolated directly from animal tissues and retain many of their original physiological properties, making them a valuable tool for in vitro studies and preclinical research. Researchers commonly use animal primary cells to study biological processes, screen drugs, and develop new disease therapies. The advantages of using animal primary cells include ease of availability, low cost compared to human primary cells, and the ability to model species-specific responses to treatments. Human primary cells are derived directly from human tissues and maintain many characteristics similar to their origin tissue. They are essential for understanding human biology, drug discovery, pathology, toxicity testing, and regenerative medicine applications. Human primary cell cultures provide more accurate representations of human cellular responses than immortalized cell lines or animal models. Human primary cells are often preferred for applications requiring a higher biological relevance, especially when studying human-specific diseases or developing patient therapies.

Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing

Dermatocytes are essential for researchers studying skin biology, wound healing, and dermatological disorders. They are widely used in drug development and toxicity testing. Gastrointestinal cells encompass a variety of cell types found in the gastrointestinal tract and are vital for research on gut health, nutrient absorption, and digestive disorders. Cardiomyocytes or heart cells are central to cardiovascular research involving cardiac development, function, and disease modeling. Hematopoietic stem cells (HSCs) give rise to all blood cell types and have diverse applications in regenerative medicine & transplantation therapies for hematological disorders such as leukemia or lymphoma. Primary hepatocytes are crucial to research involving liver function, metabolism, and toxicity testing of pharmaceuticals. Pulmonary research relies heavily on primary lung cells for studying respiratory diseases such as asthma, COPD, or lung cancer. Musculoskeletal cells consist of bone, cartilage, and muscle-forming cells and are imperative in musculoskeletal disorder studies, regenerative medicine applications & tissue engineering solutions. Kidney or renal primary cells offer insightful models for nephrology research, including kidney disease progression & drug toxicity assessment on renal functions.

End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation

Life science companies, including biotechnology, pharmaceutical, and medical device industries, heavily invest in research and development activities. These companies require primary cells for drug discovery, toxicity testing, cell therapy development, regenerative medicine applications, and manufacturing biological products. These companies involve high-quality primary cells with well-characterized phenotypes to ensure accurate results during experimentation. Research institutes encompass academic institutions and government-funded laboratories focused on understanding fundamental biological processes and disease mechanisms. Primary cells are essential to their research efforts due to their relevance as model systems in studying cellular processes or responses under various experimental conditions. The preference of research institutes revolves around the availability of diverse primary cell types, sourced ethically and with proper documentation, to ensure reproducibility across different laboratories.

Regional Insights

Americas region showcases significant growth primarily due to the presence of well-established biotechnology and pharmaceutical industries in countries such as the United States and Canada. The rapid adoption of advanced technologies in cell culture methodologies and increasing investments in research & development activities contribute to this region's strong performance. Furthermore, several government initiatives aimed at promoting novel therapies using primary cells have spurred growth in this sector. In the APAC region, countries such as China and India are experiencing considerable expansion of their biopharmaceutical sectors. This is attributed to factors such as a growing elderly population with a higher prevalence of chronic diseases requiring innovative treatment options, increased healthcare expenditure, and a greater focus on research & development activities. As a result, there has been a surge in demand for primary cells within this region. Additionally, Japan boasts a strong presence in regenerative medicine research, which has led to increased utilization of primary cells for therapeutic purposes. Europe is experiencing significant growth with its robust R&D framework supported by substantial investments from both governmental organizations and private entities. Countries such as Germany, France, Italy, UK, Spain, and the Netherlands have all contributed significantly through their respective biotechnology pharmaceutical industries, shaping up an overall progressive scenario within the EMEA region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Primary Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Primary Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Primary Cells Market, highlighting leading vendors and their innovative profiles. These include Biopredic International, Corning Incorporated, Danaher Corporation, FUJIFILM Irvine Scientific, Inc., Lonza AG, PromoCell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, The Bio Convergence Company, The Merck Group, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Primary Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Origin
    • Animal Primary Cells
    • Human Primary Cells
  • Cell Type
    • Dermatocytes
    • Gastrointestinal Cells
    • Heart Cells
    • Hematopoietic Cells
    • Hepatocytes
      • Cryopreserved Hepatocytes
      • Fresh Hepatocytes
    • Lung Cells
    • Musculoskeletal Cells
    • Renal Cells
  • End-User
    • Life Science Companies
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Primary Cells Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Primary Cells Market?

3. What are the technology trends and regulatory frameworks in the Primary Cells Market?

4. What is the market share of the leading vendors in the Primary Cells Market?

5. Which modes and strategic moves are suitable for entering the Primary Cells Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing acceptance in drug screening and cell based assays
      • 5.1.1.2. Advantages of primary human cells over other existing methods
      • 5.1.1.3. Growing focus on monoclonal antibodies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Common cell culture problems such as contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding biotechnology and biopharmaceutical industries
      • 5.1.3.2. Advancements in biomedical research using primary cells
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues in cell biology research field
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Origin: Increasing preference for human primary cells for accurate representations of human cellular responses
    • 5.2.2. Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing
    • 5.2.3. End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Primary Cells Market, by Origin

  • 6.1. Introduction
  • 6.2. Animal Primary Cells
  • 6.3. Human Primary Cells

7. Primary Cells Market, by Cell Type

  • 7.1. Introduction
  • 7.2. Dermatocytes
  • 7.3. Gastrointestinal Cells
  • 7.4. Heart Cells
  • 7.5. Hematopoietic Cells
  • 7.6. Hepatocytes
  • 7.7. Lung Cells
  • 7.8. Musculoskeletal Cells
  • 7.9. Renal Cells

8. Primary Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Life Science Companies
  • 8.3. Research Institutes

9. Americas Primary Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Primary Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Primary Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Primary Human Cells for Microphysiological Systems
    • 12.3.2. AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
    • 12.3.3. Human Cell Design Launches Endoc-BH5, an Advanced Human Beta Cell Model enabling New Discoveries in Type 1 and 2 Diabetes Research
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PRIMARY CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. PRIMARY CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PRIMARY CELLS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRIMARY CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PRIMARY CELLS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 359. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 360. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 361. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 362. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 369. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 370. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2023 (USD MILLION)
  • TABLE 372. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2024-2030 (USD MILLION)
  • TABLE 373. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2023 (USD MILLION)
  • TABLE 374. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2024-2030 (USD MILLION)
  • TABLE 375. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2023 (USD MILLION)
  • TABLE 376. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2024-2030 (USD MILLION)
  • TABLE 377. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 378. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 379. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 380. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023